Jump to content

Drilldown: Medicines

Choose a table:


Medicines > generic: None & classes : 5HT2A or Dissociative

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
Rexulti (1) · Spravato (1)
classes: (Click arrow to add another value)
mechanism:
None (1) · Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1)
uses:
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)
starting dose:
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) · Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1)
preparations:
0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1) · 28 mg/device (each dose uses 2 devices) (1)
fda max:
4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct) (1) · 84 mg per session (1)
routes:
Intranasal (under direct medical supervision) (1) · Oral (1)
onset:
Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1) · Within hours of first administration (1)
duration:
Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) · Daily dosing (1)
halflife:
~7-12 hours (1) · ~91 hours (1)
bioavailability:
~48% intranasal (1) · ~95% (1)
pregnancy:
Avoid; may cause fetal harm (1) · Limited data; National Pregnancy Registry available (1)
legal:
Rx (1) · Rx, Schedule III (US). REMS program required. (1)

Showing below up to 2 results in range #1 to #2.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"